Diphenidine and Schedule I: What DEA’s Proposed Rule Means Right Now
Diphenidine isn’t scheduled yet. DEA proposed placing it in Schedule I on May 26, 2026, but this is a proposed rule, not a final one. Nothing changes for anyone handling this substance until DEA acts again.
What Is Diphenidine and Why Does DEA Want to Schedule It?
Diphenidine is a synthetic dissociative drug first made in 1924 but not seen on the illicit market until 2014. It works like PCP and ketamine, blocking NMDA receptors in the brain. DEA found it in 11 states, mostly sold online as a “research chemical” or “legal high.”
DEA’s own eight-factor analysis found high abuse potential, no accepted medical use, and no established safety profile under medical supervision. At least five deaths have been linked to diphenidine use, alongside effects like agitation, disorientation, and dissociation.
Is This Rule Actually in Effect?
No. This is a Notice of Proposed Rulemaking, published as 91 FR 30519 (Docket No. DEA1155). It’s step one of a formal process, not a done deal.
The public comment period closed June 25, 2026. Until DEA issues and publishes a final rule, diphenidine remains not federally scheduled under the CSA.
What Happens If the Rule Gets Finalized?
Anyone who manufactures, distributes, imports, exports, researches, or possesses diphenidine would need DEA registration. Current researchers already registered for another Schedule I substance would get a 90-day window after the final rule takes effect to file for diphenidine specifically.
Anyone unwilling or unable to register would need to surrender existing stock to a registered party before the rule takes effect. Retail sale to the public would become illegal outright, as it already is for all Schedule I substances.
Who Actually Needs to Pay Attention Right Now?
DEA identified only three domestic suppliers of diphenidine, spread across pharmaceutical manufacturing, chemical wholesale, and research. If you’re not one of them, this proposed rule has no direct impact on your business today.
Telehealth platforms, pharmacies, and clinical practices aren’t affected by this proposed rule unless they specifically handle diphenidine — it has no FDA-approved use and isn’t part of any legitimate treatment protocol. The people who need to act now are researchers and labs currently working with this specific compound, not general healthcare providers.
- Check whether your organization currently handles diphenidine in any research or supply capacity.
- If you do, prepare your DEA registration application now rather than waiting for a final rule.
- Watch for DEA’s final rule, since the comment window has already closed.
- Track Federal Register Docket No. DEA1155 for the final rule and its effective date.
- Consult your compliance counsel.
Source
This post is for educational purposes only and does not constitute legal or compliance advice. Consult a qualified attorney or compliance professional before acting on this information.
